Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy

Mankan, Arun K.,Mankan, Nagender,de las Heras, Begona,Ramkissoon, Shakti H.,Bodriagova, Olga,Vidal, Laura,Grande, Enrique,Saini, Kamal S.

DOI: https://doi.org/10.1007/s12325-023-02758-w

2024-01-11

Advances in Therapy

Abstract:Immune checkpoint inhibitors (ICI) have emerged as an important therapeutic approach for patients with cancers including bladder cancer (BC). This commentary describes a recent study that demonstrated that the loss of Y chromosome (LOY) and/or loss of specific genes on Y chromosome confers an aggressive phenotype to BC because of T cell dysfunction resulting in CD8 + T cell exhaustion. Loss of expression of Y chromosome genes KDM5D and UTY was similarly associated with an unfavorable prognosis in patients with BC as these genes were partially responsible for the impaired anti-tumor immunity in LOY tumors. From a clinical perspective, the study showed that tumors with LOY may be susceptible to treatment with ICIs.

pharmacology & pharmacy,medicine, research & experimental